Following its Series A financing, BioFlyte welcomes national security and public safety executive Todd Sickles as CEO to accelerate productization and market penetration of its disruptive biodetection technology
Sickles most recently served as CEO of Tsymmetry, a Washington DC-based IT consulting and services provider to the federal government, primarily in the homeland security and public sector space. During the ten years he served as CEO, he oversaw and grew key mission-critical programs at Department of State and DHS and collaborated with various federal civilian law enforcement and intelligence agencies. Under his leadership, the firm grew over 300% and pivoted from a staff augmentation services organization to an award-winning government prime contractor. Prior to his tenure at Tsymmetry, Sickles held senior roles within business development, business unit and divisional management, and senior client relationship management at Accenture and BAE Systems IT.
Sickles brings a diverse set of skills and relevant experience to BioFlyte, as he spent the first half of his career in product development, marketing, operations, and general management roles within product-centric organizations focused on the semiconductor processing and life science business segments. He has worked internationally in Europe, the Middle East, and South America with both commercial and federal government customers.
“Todd has a proven track record of growing businesses and brings a deep understanding of the needs and requirements within the national security arena,” said David Blivin, Managing Partner of Cottonwood Technology Fund and member of the BioFlyte Board of Directors. “This is an exciting time for BioFlyte, following its recent funding round, and with Todd at the helm, the company is in a position to push into new markets and bring the technology to new customers.”
Sickles also has a long history of community service and is actively engaged with several organizations in New Mexico, including Presbyterian Health Services in Santa Fe. He is also a member of the New Mexico Angels, a New Mexico-based group of individual accredited angel investors, where he focuses on mentoring and investing in southwestern startups in the high-tech sector.
“The BioFlyte team has developed a unique and truly disruptive biothreat identification technology based on decades of research that can transform threat detection and response across many environments,” said Todd Sickles, CEO of BioFlyte. “I have spent a large portion of my career focused on national security priorities and requirements and can see the potential of this technology within bioterrorist and other biohazard situations, in both the federal and commercial sectors. I am excited for the opportunity to help accelerate commercialization and market adoption efforts alongside the rest of the team here.”
BioFlyte’s co-founder, Dr. Charles Call, will step into the role of Chief Technology Officer and Head of Product to focus on the company’s technological development and product roadmap, and to assist in the qualification of potential new market segments for the firm’s technology.
To learn more about BioFlyte, please visit https://bioflyte.com.
BioFlyte is a bioaerosol surveillance company that is commercializing a revolutionary new class of fieldable biological contamination sampling, detection, and identification solutions. The firm’s current application focus is critical infrastructure protection and pandemic response. For more information about BioFlyte and its products, please visit: https://bioflyte.com.
Kalyn Kolek for BioFlyte – email@example.com